A new partnership has been formed between European and African researchers to develop an AIDS vaccine that can be used to prevent infection with different strains of HIV worldwide. Led by Professor Tomáš Hanke at the Jenner Institute, the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) will evaluate a new vaccine that triggers the body to produce specialised immune cells called T-cells, which will be trialled at four sites in Kenya, Uganda and Zambia.
Evaluation of PvCelTOS as a pre-erythrocytic P. vivax vaccine. Clin Vaccine Immunol. Article
Astrocytes Resist HIV-1 Fusion but Engulf Infected Macrophage Material. Cell Rep, 18 (6), pp. 1473-1483. Article
Clinical trials are an essential part of vaccine development, and our volunteers play a critical role in our studies.
If you would like to find out more about paid clinical trials, and what is involved in participating, please go to our Recruiting Trials page to see which trials are currently recruiting.
Prof William R. Jacobs: Continuing to pursue Edward Jenner‚Äôs revenge: Sterilizing vaccines in chemotherapy for tuberculosis, 27/Feb/2017 12:00
Prof Reinout van Crevel: BCG induced trained immunity through epigenetic and metabolic reprogramming, 13/Mar/2017 11:00